Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,074 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan.
Miyazawa K, Ohyashiki K, Urabe A, Hata T, Nakao S, Ozawa K, Ishikawa T, Kato J, Tatsumi Y, Mori H, Kondo M, Taniguchi J, Tanii H, Rojkjaer L, Omine M. Miyazawa K, et al. Among authors: ozawa k. Int J Hematol. 2008 Jul;88(1):73-81. doi: 10.1007/s12185-008-0115-2. Epub 2008 Jul 4. Int J Hematol. 2008. PMID: 18597054 Clinical Trial.
Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality.
Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M, Nakao S, Nakahata T, Harada M, Murate T, Ozawa K; Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes. Takatoku M, et al. Among authors: ozawa k. Eur J Haematol. 2007 Jun;78(6):487-94. doi: 10.1111/j.1600-0609.2007.00842.x. Epub 2007 Mar 28. Eur J Haematol. 2007. PMID: 17391310
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M, Ozawa K. Harada H, et al. Among authors: ozawa k. Int J Hematol. 2009 Oct;90(3):353-360. doi: 10.1007/s12185-009-0400-8. Epub 2009 Aug 25. Int J Hematol. 2009. PMID: 19705057 Clinical Trial.
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.
Kanakura Y, Ohyashiki K, Shichishima T, Okamoto S, Ando K, Ninomiya H, Kawaguchi T, Nakao S, Nakakuma H, Nishimura J, Kinoshita T, Bedrosian CL, Valentine ME, Khursigara G, Ozawa K, Omine M. Kanakura Y, et al. Among authors: ozawa k. Int J Hematol. 2011 Jan;93(1):36-46. doi: 10.1007/s12185-010-0748-9. Epub 2011 Jan 12. Int J Hematol. 2011. PMID: 21222185 Clinical Trial.
5q-syndrome in Japan.
Tasaka T, Tohyama K, Ohyashiki K, Ozawa K. Tasaka T, et al. Among authors: ozawa k. Int J Hematol. 2011 Jun;93(6):827-829. doi: 10.1007/s12185-011-0868-x. Epub 2011 May 13. Int J Hematol. 2011. PMID: 21567163 No abstract available.
2,074 results